Acumen will present Phase 1 topline data on its Alzheimer’s therapeutic candidate, ACU193, at the annual Alzheimer’s Association International Conference. ACU193 is an anti-beta amyloid with a unique ...
Acumen Pharmaceuticals has early clinical evidence that its Alzheimer’s disease candidate safely reduces amyloid plaque. But while the readout partly addresses concerns about the molecule’s activity, ...
Acumen Pharmaceuticals' ACU193 shows promise as a potential treatment for early-stage Alzheimer's Disease, targeting amyloid beta oligomers with a more favorable safety profile. Q2 earnings show ...
Phase 1 data shows sabirnetug (ACU193) is safe, reduces amyloid plaques, and supports ongoing Phase 2 trial for early Alzheimer’s disease. The press release implies that while there were positive ...
NEWTON, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback